The effect of sodium valproate on chronic daily headache and its subgroups.

摘要: The objective of the study was to assess efficacy and tolerability sodium valproate (VPA) on chronic daily headache (CDH) in a prospective, double-blind, randomized, placebo-controlled trial. Seventy patients were included study. Twenty-nine had migraine (CM) 41 tension-type (CTTH). VPA placebo applied for 3 months 40 30 patients, respectively. Visual analog scale (VAS) pain frequency (PF) used evaluation. decreased maximum VAS levels (MaxVAS) PF at end (P = 0.028 P 0.000, respectively), but did not change general (GnVAS) 0.198). In CM decreases MaxVAS, GnVAS parameters more treated 0.006, 0.03, respectively). treatment caused reduction than CTTH subgroup 0.000). is effective prophylactic CDH by reducing MaxVAS PF. It CTTH.